As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Solid Biosciences Inc. The largest reported stake is Perceptive Advisors LLC's, at 11.2%. 18 filings are on record since July 17, 2025 (Schedule 13D/A, August 14, 2026).
Who owns Solid Biosciences Inc.?
Sell to companies like Solid Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 12,036,126 · Sole dispositive: 0 · Shared dispositive: 12,036,126 · SCHEDULE 13D/A, 2026-11-06
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 12,046,579 · Sole dispositive: 0 · Shared dispositive: 12,046,579 · SCHEDULE 13D/A, 2026-08-14
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 4,833,796 · Sole dispositive: 0 · Shared dispositive: 4,833,796 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Fmr LLC · Sole voting: 6,875,423 · Shared voting: 0 · Sole dispositive: 6,875,957 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-06
- · Reporting person: BlackRock, Inc. · Sole voting: 6,328,941 · Shared voting: 0 · Sole dispositive: 6,419,730 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-30
Solid Biosciences Inc. has 18 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 11.2% | 12,046,579 | SCHEDULE 13D/A, 2026-08-14 | 2026-06-30 |
| RA Capital Management, L.P. | 10.8% | 12,036,126 | SCHEDULE 13D/A, 2026-11-06 | 2026-11-04 |
| 9.99% | 10,066,682 | SCHEDULE 13G/A, 2026-05-05 | 2026-03-31 | |
| BCLS SB Investco, LP | 8.8% | 0 | SCHEDULE 13D/A, 2026-03-10 | 2026-03-06 |
| Fmr LLC | 7% | 6,875,957 | SCHEDULE 13G, 2026-08-06 | 2026-06-30 |
| BlackRock, Inc. | 6.5% | 6,419,730 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| Vestal Point Capital, LP | 4.8% | 4,833,796 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Adage Capital Management, L.P. | 1.8% | 1,400,000 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Commodore Capital LP | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Solid Biosciences Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Solid Biosciences Inc. and the records around it.
Solid Biosciences Inc. elsewhere on the record
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Watch Solid Biosciences Inc.
Get an email when Solid Biosciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Solid Biosciences Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Solid Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Solid Biosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | 12,046,579 | 0 | 12,046,579 | SCHEDULE 13D/A, 2026-08-14 |
| Joseph Edelman | 0 | 12,046,579 | 0 | 12,046,579 | SCHEDULE 13D/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 11,973,472 | 0 | 11,973,472 | SCHEDULE 13D/A, 2026-08-14 |
| Perceptive Xontogeny Venture Fund, LP | 0 | 73,107 | 0 | 73,107 | SCHEDULE 13D/A, 2026-08-14 |
| RA Capital Management, L.P. | 0 | 12,036,126 | 0 | 12,036,126 | SCHEDULE 13D/A, 2026-11-06 |
| Peter Kolchinsky | 0 | 12,036,126 | 0 | 12,036,126 | SCHEDULE 13D/A, 2026-11-06 |
| Rajeev Shah | 0 | 12,036,126 | 0 | 12,036,126 | SCHEDULE 13D/A, 2026-11-06 |
| RA Capital Healthcare Fund, L.P. | 0 | 11,897,896 | 0 | 11,897,896 | SCHEDULE 13D/A, 2026-11-06 |
| Fmr LLC | 6,875,423 | 0 | 6,875,957 | 0 | SCHEDULE 13G, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 6,875,957 | 0 | SCHEDULE 13G, 2026-08-06 |
| BlackRock, Inc. | 6,328,941 | 0 | 6,419,730 | 0 | SCHEDULE 13G, 2026-07-30 |
| Vestal Point Capital, LP | 0 | 4,833,796 | 0 | 4,833,796 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 4,833,796 | 0 | 4,833,796 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Solid Biosciences Inc. by CUSIP 83422E204 and gives its principal executive office as 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129 (SCHEDULE 13D/A, 2026-11-06).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 6.1% | SCHEDULE 13G |
| 2025-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13D/A |
| 2025-08-14 | Commodore Capital LP | 0% | SCHEDULE 13G/A |
| 2025-11-13 | Adage Capital Management, L.P. | 5.14% | SCHEDULE 13G/A |
| 2026-02-12 | Adage Capital Management, L.P. | 1.8% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 7.5% | SCHEDULE 13G |
| 2026-03-10 | BCLS SB Investco, LP | 8.8% | SCHEDULE 13D/A |
| 2026-03-10 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13D/A |
| 2026-03-11 | Perceptive Advisors LLC | 12.9% | SCHEDULE 13D/A |
| 2026-03-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13D/A |
| 2026-04-27 | BlackRock, Inc. | 4.7% | SCHEDULE 13G/A |
| 2026-05-05 | Raymond Debbane | 9.99% | SCHEDULE 13G/A |
| 2026-06-24 | RA Capital Management, L.P. | 11.9% | SCHEDULE 13D/A |
| 2026-07-30 | BlackRock, Inc. | 6.5% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 7% | SCHEDULE 13G |
| 2026-08-14 | Vestal Point Capital, LP | 4.8% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 11.2% | SCHEDULE 13D/A |
| 2026-11-06 | RA Capital Management, L.P. | 10.8% | SCHEDULE 13D/A |
Questions about who owns Solid Biosciences Inc.
Who owns Solid Biosciences Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Solid Biosciences Inc.: Perceptive Advisors LLC (11.2%, Schedule 13D/A, filed 2026-08-14), RA Capital Management, L.P. (10.8%, Schedule 13D/A, filed 2026-11-06), Raymond Debbane (9.99%, Schedule 13G/A, filed 2026-05-05), BCLS SB Investco, LP (8.8%, Schedule 13D/A, filed 2026-03-10) and Fmr LLC (7%, Schedule 13G, filed 2026-08-06); 1 more is listed above.
Who are the largest shareholders of Solid Biosciences Inc.?
By the share each holder's latest filing reports, the largest holders of Solid Biosciences Inc. on this page are Perceptive Advisors LLC (11.2%), RA Capital Management, L.P. (10.8%) and Raymond Debbane (9.99%).
When did Perceptive Advisors LLC buy into Solid Biosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13D/A, filed 2026-03-11, reporting 12.9%; its latest, Schedule 13D/A filed 2026-08-14, reports 11.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Solid Biosciences Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Solid Biosciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.